NCT00323934View on ClinicalTrials.gov

Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2008

Conditions
TumorsNon Hodgkin's Lymphoma
Interventions
DRUG

MGCD0103

Oral dosage 2 times weekly.

Trial Locations (3)

21205

The Johns Hopkins Hospital, Baltimore

M5G 2M9

Princess Margaret Hospital, Toronto

J4V 2H1

Hopital Charles LeMoyne, Greenfield Park

Sponsors
All Listed Sponsors
lead

Mirati Therapeutics Inc.

INDUSTRY

NCT00323934 - Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter